Is lenalidomide a chemotherapy drug or a targeted drug?

Lenalidomide (Lenalidomide) is a targeted therapy drug that plays an important role in the field of tumor treatment. Although it does have a certain degree of chemotherapy effect, its mechanism of action is significantly different from traditional chemotherapy drugs.

First of all, the mechanism of action of lenalidomide is mainly to inhibit the growth and spread of tumors by regulating the immune system. It can enhance the body's immune response and promote the recognition and elimination of tumor cells by immune cells. In addition, lenalidomide inhibits the angiogenesis process, thereby reducing the blood supply to tumors and limiting their growth.

Secondly, lenalidomide has more controllable and fewer side effects than traditional chemotherapy drugs. Traditional chemotherapy drugs usually directly kill tumor cells through toxic effects, but they can also cause extensive damage to normal cells, leading to a series of serious side effects, such as nausea, vomiting, hair loss, etc. The side effects of lenalidomide are relatively mild, including mild anemia, thrombocytopenia, etc., and can be effectively controlled through monitoring and dose adjustment.

In addition, lenalidomide is often used as a targeted therapy in combination with other drugs to improve the therapeutic effect. For example, in the treatment of multiple myeloma, lenalidomide is often combined with dexamethasone (Dexamethasone) and other targeted drugs such as rituximab (Rituximab) or boron neutron capture therapy (Bortezomib) to achieve better therapeutic effects.

Therefore, as a targeted therapy drug, lenalidomide can not only effectively inhibit the growth and spread of tumors, but also has relatively mild side effects. It is one of the important drugs in tumor treatment.